Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22059856 | 0.93 | ABL1 (0.46) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL19933610 | 0.93 | ABL1 (0.46) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL18573235 | 0.88 | ABL1 (0.54) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL21721909 | 0.88 | ABL1 (0.43) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL21125955 | 0.88 | ABL1 (0.45) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL19933655 | 0.88 | ABL1 (0.43) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL21721929 | 0.86 | CHEK2 (0.42) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL21397866 | 0.86 | ABL1 (0.43) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL19933690 | 0.85 | NPC1 (0.43) | ABL1BCRKDM4EKMT2ATRPV1 | |
| SCHEMBL18573168 | 0.85 | OXTR (0.49) | ABL1BCRKDM4EKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11031562-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| WO-2017032439-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11031562-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | ABL1 1894/4885BCR 3772/4885KDM4E 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.